CG Oncology CGON
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
CG Oncology (CGON) Core Market Data and Business Metrics
Latest Closing Price
$22.24Price-Earnings Ratio
-15.77Total Outstanding Shares
76.22 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
400 Spectrum Center Drive, Irvine, CA, 92618
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 731,131 Shares | 9.89 | 3/14/2025 | 7,228,628 Shares |
| 497,933 Shares | 14.06 | 2/28/2025 | 6,999,756 Shares |
| 380,330 Shares | 18.61 | 2/14/2025 | 7,077,619 Shares |
| 594,838 Shares | 11.4 | 1/31/2025 | 6,782,886 Shares |
| 748,304 Shares | 8.52 | 1/15/2025 | 6,374,498 Shares |
| 978,998 Shares | 7.05 | 12/31/2024 | 6,898,883 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-300.76 Million |
| Net Cash Flow | $248.80 Million |
| Net Cash Flow, Continuing | $248.80 Million |
| Net Cash Flow From Investing Activities | $-300.76 Million |
| Net Cash Flow From Operating Activities, Continuing | $-78.71 Million |
| Net Cash Flow From Financing Activities | $628.28 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Costs And Expenses | $89.18 Million |
| Net Income/Loss | $-88.04 Million |
| Operating Expenses | $115.81 Million |
| Revenues | $1.14 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-88.04 Million |
| Comprehensive Income/Loss | $-88.04 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities | $21.42 Million |
| Equity | $733.38 Million |
| Other Non-current Assets | $315,000 |
| Equity Attributable To Parent | $733.38 Million |
| Current Assets | $754.21 Million |
| Noncurrent Liabilities | $52,000 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||